Xeris Biopharma (XERS) CFO sells 5,000 shares in Rule 10b5-1 trade

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. reported that its Chief Financial Officer, Steven Pieper, sold 5,000 shares of common stock on August 12, 2026 at a price of $8.50 per share. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025. Following this sale, Pieper continues to hold 1,361,053 shares of Xeris Biopharma common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Pieper Steven

Role See Remarks

Sold 5,000 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,000	$8.50	$43K

Holdings After Transaction: Common Stock — 1,361,053 shares (Direct)

Footnotes (1)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

Key Figures

Shares sold: 5,000 shares Sale price: $8.50 per share Shares held after transaction: 1,361,053 shares +1 more

4 metrics

Shares sold 5,000 shares Common Stock sale on August 12, 2026 by CFO Steven Pieper

Sale price $8.50 per share Reported price for the 5,000-share sale of Common Stock

Shares held after transaction 1,361,053 shares Directly owned Common Stock following the reported sale

10b5-1 plan adoption date August 18, 2025 Date CFO’s Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, Common Stock, Sale in open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Common Stock financial

"security_title: Common Stock for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

What insider transaction did Xeris Biopharma (XERS) disclose for Steven Pieper?

Xeris Biopharma disclosed that its CFO, Steven Pieper, sold 5,000 shares of common stock on August 12, 2026 at $8.50 per share, in a reported open-market or private sale transaction.

How many XERS shares does CFO Steven Pieper hold after this Form 4 transaction?

After the reported sale, CFO Steven Pieper holds 1,361,053 shares of Xeris Biopharma common stock directly, according to the Form 4’s post-transaction ownership figure.

Was the Xeris Biopharma (XERS) CFO’s 5,000-share sale under a Rule 10b5-1 plan?

Yes. The filing states the 5,000-share sale was executed under a Rule 10b5-1 trading plan adopted by Steven Pieper on August 18, 2025, indicating it was pre-arranged.

What was the sale price in the latest Xeris Biopharma (XERS) insider trade?

The reported sale by Xeris Biopharma’s CFO was executed at a price of $8.50 per share for 5,000 shares of common stock, as disclosed in the Form 4 transaction details.

What type of transaction did Xeris Biopharma (XERS) report for its CFO on August 12, 2026?

The company reported a sale of 5,000 common shares by CFO Steven Pieper on August 12, 2026, categorized as a “Sale in open market or private transaction” with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:45 PM Accepted by SEC EDGAR 08/12/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pieper Steven

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		S(1)		5,000	D	$8.5	1,361,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

Remarks:

Chief Financial Officer

	/s/ Beth Hecht, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)